 Warren Capell
Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rivaroxaban | 12 | 2022 | 211 | 2.230 |
Why?
| | Peripheral Arterial Disease | 12 | 2022 | 380 | 1.770 |
Why?
| | Factor Xa Inhibitors | 6 | 2021 | 138 | 1.240 |
Why?
| | Lower Extremity | 9 | 2022 | 335 | 1.200 |
Why?
| | Aspirin | 10 | 2022 | 324 | 1.200 |
Why?
| | Endovascular Procedures | 5 | 2022 | 268 | 0.940 |
Why?
| | Thrombosis | 2 | 2022 | 297 | 0.750 |
Why?
| | Beneficence | 1 | 2021 | 18 | 0.740 |
Why?
| | Hypertriglyceridemia | 3 | 2006 | 34 | 0.730 |
Why?
| | Research Subjects | 1 | 2021 | 40 | 0.720 |
Why?
| | Personal Autonomy | 1 | 2021 | 39 | 0.720 |
Why?
| | Informed Consent | 2 | 2021 | 161 | 0.720 |
Why?
| | Patient Selection | 2 | 2021 | 641 | 0.670 |
Why?
| | Ischemia | 5 | 2022 | 362 | 0.630 |
Why?
| | Outpatients | 1 | 2021 | 327 | 0.590 |
Why?
| | Platelet Aggregation Inhibitors | 8 | 2022 | 400 | 0.580 |
Why?
| | Venous Thromboembolism | 3 | 2023 | 231 | 0.470 |
Why?
| | Hospitalization | 2 | 2021 | 1751 | 0.420 |
Why?
| | Lipoproteins | 4 | 2010 | 160 | 0.400 |
Why?
| | Lipoprotein Lipase | 2 | 2010 | 54 | 0.400 |
Why?
| | Risk Assessment | 1 | 2021 | 2973 | 0.390 |
Why?
| | Hypolipidemic Agents | 3 | 2006 | 87 | 0.370 |
Why?
| | Double-Blind Method | 6 | 2021 | 1662 | 0.370 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2010 | 27 | 0.350 |
Why?
| | Hemorrhage | 5 | 2023 | 618 | 0.290 |
Why?
| | Triglycerides | 3 | 2010 | 470 | 0.280 |
Why?
| | Drug Therapy, Combination | 5 | 2021 | 954 | 0.270 |
Why?
| | Glucose | 1 | 2010 | 897 | 0.250 |
Why?
| | Myocardial Infarction | 2 | 2022 | 927 | 0.240 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2010 | 151 | 0.210 |
Why?
| | Muscle, Skeletal | 2 | 2010 | 1472 | 0.210 |
Why?
| | Fenofibrate | 1 | 2003 | 24 | 0.210 |
Why?
| | Male | 19 | 2023 | 55554 | 0.210 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 80 | 0.210 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 50 | 0.210 |
Why?
| | Middle Aged | 13 | 2023 | 26747 | 0.210 |
Why?
| | Multicenter Studies as Topic | 2 | 2021 | 249 | 0.200 |
Why?
| | Drug-Eluting Stents | 1 | 2021 | 62 | 0.190 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 192 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 82 | 0.180 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2021 | 47 | 0.180 |
Why?
| | Female | 17 | 2023 | 59483 | 0.180 |
Why?
| | Humans | 27 | 2023 | 114709 | 0.180 |
Why?
| | Clinical Trials as Topic | 3 | 2021 | 934 | 0.180 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4420 | 0.180 |
Why?
| | Paclitaxel | 1 | 2021 | 190 | 0.180 |
Why?
| | Placebos | 1 | 2021 | 198 | 0.180 |
Why?
| | Extremities | 1 | 2021 | 113 | 0.170 |
Why?
| | Vasodilation | 1 | 2003 | 415 | 0.170 |
Why?
| | Cause of Death | 1 | 2021 | 362 | 0.160 |
Why?
| | Vascular Surgical Procedures | 1 | 2021 | 257 | 0.150 |
Why?
| | Subacute Care | 1 | 2019 | 71 | 0.150 |
Why?
| | Treatment Outcome | 6 | 2022 | 9089 | 0.150 |
Why?
| | Brain Ischemia | 1 | 2021 | 299 | 0.150 |
Why?
| | Nursing Homes | 1 | 2019 | 136 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2021 | 1846 | 0.150 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2018 | 62 | 0.140 |
Why?
| | Hospital Mortality | 1 | 2021 | 776 | 0.140 |
Why?
| | Health Services Research | 1 | 2019 | 371 | 0.140 |
Why?
| | Lipoproteins, LDL | 1 | 1996 | 128 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1214 | 0.130 |
Why?
| | Skilled Nursing Facilities | 1 | 2017 | 121 | 0.120 |
Why?
| | Insulin Resistance | 3 | 2013 | 1072 | 0.120 |
Why?
| | Consensus | 1 | 2017 | 535 | 0.120 |
Why?
| | Fibrinolytic Agents | 1 | 2017 | 233 | 0.120 |
Why?
| | Ethics, Research | 1 | 2014 | 34 | 0.110 |
Why?
| | Anticoagulants | 3 | 2023 | 547 | 0.110 |
Why?
| | Societies, Medical | 1 | 2017 | 663 | 0.110 |
Why?
| | Disease Management | 1 | 2017 | 560 | 0.110 |
Why?
| | Cardiovascular Diseases | 2 | 2021 | 1727 | 0.110 |
Why?
| | Stroke | 1 | 2021 | 1019 | 0.110 |
Why?
| | Caspase 1 | 1 | 2013 | 140 | 0.100 |
Why?
| | Aged | 8 | 2022 | 19078 | 0.100 |
Why?
| | Interleukin-18 | 1 | 2013 | 219 | 0.100 |
Why?
| | Heparin | 2 | 2023 | 222 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 931 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2021 | 2127 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 585 | 0.090 |
Why?
| | Interleukin-1beta | 1 | 2013 | 370 | 0.090 |
Why?
| | Arteries | 2 | 2022 | 247 | 0.090 |
Why?
| | Transfection | 2 | 2010 | 870 | 0.090 |
Why?
| | Dietary Fats | 2 | 2010 | 287 | 0.090 |
Why?
| | Lactones | 1 | 2010 | 54 | 0.090 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2010 | 28 | 0.090 |
Why?
| | Myoblasts | 1 | 2010 | 76 | 0.090 |
Why?
| | Diet, Fat-Restricted | 2 | 2010 | 73 | 0.080 |
Why?
| | Obesity | 2 | 2013 | 2513 | 0.080 |
Why?
| | Hypercholesterolemia | 1 | 2010 | 90 | 0.080 |
Why?
| | Inflammation | 2 | 2023 | 2481 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 815 | 0.080 |
Why?
| | Palliative Care | 1 | 2014 | 641 | 0.080 |
Why?
| | Blotting, Western | 1 | 2010 | 1151 | 0.070 |
Why?
| | Adult | 5 | 2021 | 30542 | 0.070 |
Why?
| | Simvastatin | 1 | 2006 | 59 | 0.070 |
Why?
| | Temperance | 1 | 2005 | 13 | 0.070 |
Why?
| | Cross-Over Studies | 2 | 2006 | 440 | 0.060 |
Why?
| | Weight Loss | 1 | 2010 | 642 | 0.060 |
Why?
| | Anticholesteremic Agents | 1 | 2006 | 128 | 0.060 |
Why?
| | Cell Line | 1 | 2010 | 2639 | 0.060 |
Why?
| | Treatment Failure | 1 | 2005 | 332 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2006 | 362 | 0.060 |
Why?
| | Incidence | 2 | 2021 | 2312 | 0.060 |
Why?
| | Heart Failure | 1 | 2017 | 1952 | 0.060 |
Why?
| | Thromboplastin | 1 | 2023 | 71 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 372 | 0.050 |
Why?
| | Forearm | 1 | 2003 | 112 | 0.050 |
Why?
| | Vesicular Transport Proteins | 1 | 2003 | 83 | 0.050 |
Why?
| | Metabolic Syndrome | 1 | 2005 | 323 | 0.050 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 8 | 0.050 |
Why?
| | Fasting | 1 | 2003 | 242 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2003 | 424 | 0.050 |
Why?
| | Postmenopause | 1 | 2003 | 303 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2021 | 181 | 0.040 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2003 | 411 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2003 | 446 | 0.040 |
Why?
| | Internationality | 1 | 2020 | 144 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2005 | 654 | 0.040 |
Why?
| | Mice | 3 | 2013 | 14916 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2003 | 529 | 0.040 |
Why?
| | Algorithms | 1 | 2006 | 1468 | 0.040 |
Why?
| | Confidentiality | 1 | 2019 | 67 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 288 | 0.040 |
Why?
| | Acute Disease | 1 | 2021 | 912 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 1393 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1080 | 0.040 |
Why?
| | Proteins | 1 | 2003 | 912 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2003 | 1022 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1122 | 0.040 |
Why?
| | Cholesterol, LDL | 2 | 2010 | 307 | 0.030 |
Why?
| | Risk Factors | 2 | 2022 | 8625 | 0.030 |
Why?
| | Arteriosclerosis | 1 | 1996 | 82 | 0.030 |
Why?
| | Patient Safety | 1 | 2019 | 278 | 0.030 |
Why?
| | Particle Size | 1 | 1996 | 317 | 0.030 |
Why?
| | Patient Transfer | 1 | 2017 | 144 | 0.030 |
Why?
| | Reference Values | 1 | 1996 | 741 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1996 | 316 | 0.030 |
Why?
| | Animals | 3 | 2013 | 31761 | 0.030 |
Why?
| | Ethics Committees, Research | 1 | 2014 | 38 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2006 | 2096 | 0.030 |
Why?
| | Research Personnel | 1 | 2014 | 151 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 4899 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2013 | 225 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6215 | 0.020 |
Why?
| | Diet, Reducing | 1 | 2010 | 76 | 0.020 |
Why?
| | Quality Improvement | 1 | 2017 | 951 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2010 | 139 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 869 | 0.020 |
Why?
| | Communication | 1 | 2014 | 747 | 0.020 |
Why?
| | Phenotype | 1 | 1996 | 2811 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1717 | 0.020 |
Why?
| | Energy Intake | 1 | 2010 | 427 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 2582 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2003 | 12511 | 0.020 |
Why?
| | Dyslipidemias | 1 | 2006 | 154 | 0.020 |
Why?
| | Munc18 Proteins | 1 | 2003 | 23 | 0.010 |
Why?
| | SNARE Proteins | 1 | 2003 | 37 | 0.010 |
Why?
| | Time Factors | 1 | 2013 | 6122 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2003 | 185 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 743 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 928 | 0.010 |
Why?
| | Insulin | 1 | 2010 | 2079 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2003 | 1951 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2003 | 3890 | 0.010 |
Why?
| | Blood Glucose | 1 | 2003 | 1821 | 0.010 |
Why?
|
|
Capell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|